Crinetics Pharma's Oral Treatment Offers Long-Lasting Relief for Acromegaly Patients in New Trial; Market Excitement Grows

Rumors circulating in retail circles about Crinetics Pharmaceuticals increased late Sunday following the release of extended data for its orally administered treatment for acromegaly, Palsonify (paltusotine), which demonstrated ongoing biochemical management and improvement in symptoms from two Phase 3 trials.

During the ENDO 2025 meeting, Crinetics presented updated findings from its continuing PATHFNDR-1 and PATHFNDR-2 trials, indicating that individuals who transitioned from monthly shots to daily oral doses of Palsonify maintained stable levels of insulin-like growth factor 1 (IGF-1) and growth hormone over almost two years.

Symptom ratings, using the acromegaly symptom diary (ASD), stayed consistent as well. Palsonify was typically easy to tolerate.

In PATHFNDR-2, which focused on individuals with uncontrolled acromegaly, Palsonify resulted in long-term decreases in IGF-1 levels and fewer symptom flare-ups over an 84-week period.

Significantly, individuals who were initially on a placebo showed substantial progress once they transitioned to Palsonify during the open-label extension phase.

A combined review of symptom ratings from both studies revealed a notable reduction in daily symptoms for patients who transitioned from injections to consistent Palsonify use, with flare-ups dropping from more than 30% of days when using somatostatin receptor ligands (SRLs) to only 6.2% under steady-state Palsonify administration, irrespective of initial disease management or prior therapy.

CEO Scott Struthers stated that the findings highlight Palsonify's promise as a daily, advanced therapy for acromegaly.

Crinetics is further developing Palsonify in a Phase 3 study for carcinoid syndrome among individuals with neuroendocrine tumors, building upon encouraging outcomes from Phase 2 trials related to flushing and managing bowel movements.

In March, the European Medicines Agency (EMA) approved Crinetics' market approval request (MAA) for Palsonify as a sustained treatment option for acromegaly.

The European Medicines Agency had earlier provided the medication with Orphan Drug Status in February.

On [date], retail interest in Crinetics was 'positive' with 'significant' levels of communication.

The shares of Crinetics have dropped by 38.1% this year in 2025.

See also: Trump's 35 Percent Tax Warning Sends Waves Through Walmart's Bangladeshi Supplier Network: Study

To receive updates and revisions, send an email to newsroom[at][dot]com.

Berbagi :